The deregistration is the final step in the going-private transaction. No further public trading or SEC filings are expected. Shareholders who tendered shares in the merger have already received the $3.16 per share plus CVR consideration. Monitor for any post-merger CVR events or appraisal rights deadlines.
Price Chart
Executive Summary
Esperion Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g), effective immediately. This is the final procedural step following the company's delisting from Nasdaq on July 13, 2026, after its acquisition by ArchiMed (via Essence Parent Inc.). With only 1 holder of record, the company will cease all SEC reporting obligations, completing its transition to a private entity.
Key Facts
- Form 15-12G filed to terminate registration under Section 12(g) of the Securities Exchange Act of 1934.
- Approximate number of holders of record as of the certification date: 1.
- Filing follows a 25-NSE delisting from Nasdaq on July 13, 2026, related to the acquisition by ArchiMed.
- The company will no longer file periodic reports with the SEC (Forms 10-K, 10-Q, 8-K, etc.).
Financial Impact
No financial figures provided in the filing. The deregistration is a procedural step after the completed acquisition; the company is now private.
Risk Factors
- No ongoing public disclosure or SEC oversight for the company.
- Minority shareholders who did not tender may face illiquidity and limited information rights.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 15-12G Filing (Primary) | 0001104659-26-086097 |
| Document: 0001104659-26-086097-index-headers.html | 0001104659-26-086097 |
| Document: 0001104659-26-086097-index.html | 0001104659-26-086097 |
| Document: 0001104659-26-086097.txt | 0001104659-26-086097 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | Court Ruling | โ | awaiting T+5 | โ | โ |
Aug 13, 2026 7w ago | Institutional Cluster | โ | awaiting T+5 | โ | โ |
Jul 23, 2026 10w ago | 15-12G | โ | awaiting T+5 | โ | โ |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | โ | โ |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | โ | โ |
Jul 13, 2026 11w ago | 25-NSE | $3.19 awaiting T+5 | awaiting T+5 | โ | โ |
Jul 13, 2026 11w ago | 8-K | $3.19 awaiting T+5 | awaiting T+5 | โ | โ |
Jun 16, 2026 15w ago | DEFA14A | $3.17 $3.15 | โผ โ0.63% | โฒ +0.41% | โ |
Jun 11, 2026 16w ago | Institutional Cluster | $3.15 $3.17 | โฒ +0.63% | โฒ +0.20% | โ |
Jun 9, 2026 16w ago | 8-K | $3.14 $3.16 | โฒ +0.64% | โผ โ2.80% | โ |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access